Volume 2, Issue 3, September 2017, Page: 117-121
Trends in Anticoagulation Practices Post Tissue Aortic Valve Replacement (AVR)
Sunil Stephenson, Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, UK
Sanjeet Avtaar Singh, Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, UK
Ahmed Al-Adhami, Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, UK
Rajdev Singh Toor, Department of Anaesthesiology, Fiona Stanley Hospital, Murdoch, Australia
Received: Jul. 17, 2017;       Accepted: Jul. 25, 2017;       Published: Aug. 26, 2017
DOI: 10.11648/j.bsi.20170203.15      View  1252      Downloads  62
Abstract
Biological aortic valve replacements are commonplace in cardiac surgery and is highly recommended for patients older than 65 years old as there is no need for anticoagulation. However, there is a significant incidence of post-operative atrial fibrillation in this cohort of patients which results in some surgeons preferring to anticoagulated patients for short term. The practice at a tertiary referral centre was reviewed.
Keywords
Anticoagulation, Warfarin, Tissue Aortic Valve Replacement
To cite this article
Sunil Stephenson, Sanjeet Avtaar Singh, Ahmed Al-Adhami, Rajdev Singh Toor, Trends in Anticoagulation Practices Post Tissue Aortic Valve Replacement (AVR), Biomedical Statistics and Informatics. Vol. 2, No. 3, 2017, pp. 117-121. doi: 10.11648/j.bsi.20170203.15
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ and others. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25 [5]:1111-9.
[2]
Babin-Ebell J, Schmidt W, Eigel P, Elert O. Aortic bioprosthesis without early anticoagulation--risk of thromboembolism. Thorac Cardiovasc Surg 1995; 43 [4]:212-4.
[3]
Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G, Elefteriades J. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation 1998; 98 [19 Suppl]: II 95-8; discussion II 98-9.
[4]
Orszulak TA, Schaff HV, Mullany CJ, Anderson BJ, Ilstrup DM, Puga FJ, Danielson GK. Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. The Annals of thoracic surgery 1995; 59 [2]:462-468.
[5]
Al-Atassi T, Lam K, Forgie M, Boodhwani M, Rubens F, Hendry P, Masters R, Goldstein W, Bedard P, Mesana T and others. Cerebral Microembolization After Bioprosthetic Aortic Valve Replacement: Comparison of Warfarin Plus Aspirin Versus Aspirin Only. Circulation 2012; 126 [11 suppl 1]: S239-S244.
[6]
Goldsmith I, Lip GY, Mukundan S, Rosin MD. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. J Heart Valve Dis 1998; 7 [5]:574-9.
[7]
Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D’Amico R, Beghi C. Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study. Circulation 2004; 110 [5]:496-500.
[8]
Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CGA, Puga FJ, Orszulak TA, Schaff HV. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? ACC Current Journal Review, 14(8), pp.59-60.
[9]
Blair KL, Hatton AC, White WD, Smith LR, Lowe JE, Wolfe WG, Young WG, Oldham HN, Douglas JM, Jr., Glower DD. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation 1994; 90 [5 Pt 2]: Ii 214-9.
[10]
ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg 2010; 139 [5]:1137-45.
[11]
Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin [WoA] after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007; 16 [6]:667-71.
[12]
Colli A, Verhoye JP, Heijmen R, Antunes M. Low-dose acetyl salicylic acid versus oral anticoagulation after bioprosthetic aortic valve replacement. Final report of the ACTION registry. Int J Cardiol 2013; 168 [2]:1229-36.
[13]
Duraes AR, Duraes MA, Correia LC, Fernandes AM, Aras Junior R. Impact of aspirin use in the incidence of thromboembolic events after bioprosthesis replacement in patients with rheumatic disease. Rev Bras Cir Cardiovasc 2013; 28 [3]: 347-52.
[14]
Brueck M, Kramer W, Vogt P, Steinert N, Roth P, Gorlach G, Schonburg M, Heidt MC. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 2007; 32 [1]: 108-12.
[15]
Brennan JM, Alexander KP, Wallace A, Hodges AB, Laschinger JC, Jones KW, O'Brien S, Webb LE, Dokholyan RS, Peterson ED. Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. J Heart Valve Dis 2012; 21 [1]: 8-87.
[16]
Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; 60 [11]: 971-7.
[17]
Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. Jama 2012; 308 [20]: 2118-25.
[18]
Colli A, Verhoye JP, Heijmen R, Strauch JT, Hyde JA, Pagano D, Antunes M, Koertke H, Ohri SK, Bail DH and others. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008; 33 [4]: 531-6.
[19]
Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis 2005; 14 [5]: 576-82.
[20]
Members ATF, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M and others. Guidelines on the management of valvular heart disease [version 2012]: The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology [ESC] and the European Association for Cardio-Thoracic Surgery [EACTS]. European Heart Journal 2012.
[21]
Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT and others. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease]: Developed in Collaboration With the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114 [5]: e84-e231.
Browse journals by subject